rabbit anti col3a1  (Proteintech)

Journal: Cancer immunology, immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma.

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Fig. 6 Prognostic value of LYZ and LILRB4 proteins in DLBCL receiving R-CHOP (n = 37, 10X) and aNSCLC receiving ICIs (n = 29, 2X and 10X). A Representative IHCs staining of LYZ in patient 1 (PFS = 1697 days) and patient 2 (PFS = 341 days), LILRB4 in patient 3 (PFS = 64 days) and patient 4 (PFS = 826 days). B Kaplan–Meier survival curves of PFS grouped by the LYZ and LILRB4 expression in DLBCL. C Representative mIF staining of LYZ, LILRB4, and pan Cytokeratin. D Kaplan–Meier survival curves of OS grouped by the LYZ and LILRB4 expression in aNSCLC. E Kaplan–Meier survival curves of PFS grouped by the COL3A1 expression and FN1+ mac- rophages in DLBCL. DLBCL: diffuse large B cell lymphoma; R-CHOP: rituximab, cyclo- phosphamide, doxorubicin: vincristine, and prednisone; aNSCLC: advanced non-small cell lung cancer; ICIs: immune checkpoint inhibitors; IHC: immunohistochemistry; PFS: progression-free survival; mIF: multiple immunofluorescence; and OS: overall survival

Article Snippet: Primary antibodies included rabbit anti-human IgG antibody LYZ (ab108508, dilution 1:2000, Abcam), LILRB4 (#55107, dilution 1:2000, Signalway Antibody), COL3A1 (#63034S, dilution 1:3000, Cell Signaling Technology), FN1 (#26836S, dilution 1:2000, Cell Signaling Technology), CD68 (ab303565, dilution 1:1000, Abcam), and mouse anti-human pan-cytokeratin IgG antibody (GB122053, dilution 1:2000, Servicebio) and COL1A2 (sc-393573, dilution 1:2000, Santa Cruz Biotechnology).

Techniques: Staining, Expressing, Immunohistochemistry, Immunofluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Rabbit anti-human COL3A1 IgG antibody , #63034S , Cell Signaling Technology.

Techniques: Formalin-fixed Paraffin-Embedded, Gene Expression, RNA Sequencing, Sequencing, Biomarker Discovery, Clinical Proteomics, Microarray, Control, Immunohistochemistry, Microscopy, Immunofluorescence, Software

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Prognostic value of LYZ and LILRB4 proteins in DLBCL receiving R-CHOP ( n = 37, 10X) and aNSCLC receiving ICIs ( n = 29, 2X and 10X). A Representative IHCs staining of LYZ in patient 1 (PFS = 1697 days) and patient 2 (PFS = 341 days), LILRB4 in patient 3 (PFS = 64 days) and patient 4 (PFS = 826 days). B Kaplan–Meier survival curves of PFS grouped by the LYZ and LILRB4 expression in DLBCL. C Representative mIF staining of LYZ, LILRB4, and pan Cytokeratin. D Kaplan–Meier survival curves of OS grouped by the LYZ and LILRB4 expression in aNSCLC. E Kaplan–Meier survival curves of PFS grouped by the COL3A1 expression and FN1 + macrophages in DLBCL. DLBCL: diffuse large B cell lymphoma; R-CHOP: rituximab, cyclophosphamide, doxorubicin: vincristine, and prednisone; aNSCLC: advanced non-small cell lung cancer; ICIs: immune checkpoint inhibitors; IHC: immunohistochemistry; PFS: progression-free survival; mIF: multiple immunofluorescence; and OS: overall survival

Article Snippet: Rabbit anti-human COL3A1 IgG antibody , #63034S , Cell Signaling Technology.

Techniques: Staining, Expressing, Immunohistochemistry, Immunofluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Prognostic significance of autoantibodies against COL1A2, COL3A1, and FN1 in patients with DLBCL receiving R-CHOP ( n = 20 and 125) and NSCLC treated with ICIs ( n = 36). A Volcano plot, boxplot, and representative density plots of patients illustrating the distribution of COL1A2 autoantibodies in DLBCL. B Kaplan–Meier curve for PFS based on COL1A2 autoantibody levels in DLBCL. C Kaplan–Meier curves for OS and PFS in NSCLC patients receiving immunotherapy, stratified by COL1A2 and COL3A1 mRNA levels in GSE128989 and autoantibody presence, alongside representative density plots of COL1A2 and COL3A1 autoantibodies. D Comparison of FN1 autoantibody levels between healthy controls and DLBCL, with Kaplan–Meier analysis for PFS based on FN1 autoantibody levels. DLBCL: diffuse large B cell lymphoma; R-CHOP: rituximab, cyclophosphamide, doxorubicin: vincristine, and prednisone; NSCLC: non-small cell lung cancer; ICIs: immune checkpoint inhibitor; OS: overall survival; and PFS: progression-free survival

Article Snippet: Rabbit anti-human COL3A1 IgG antibody , #63034S , Cell Signaling Technology.

Techniques: Comparison

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Rabbit anti-human COL3A1 IgG antibody , #63034S , Cell Signaling Technology.

Techniques: Formalin-fixed Paraffin-Embedded, Gene Expression, RNA Sequencing, Sequencing, Biomarker Discovery, Clinical Proteomics, Microarray, Control, Immunohistochemistry, Microscopy, Immunofluorescence, Software